Effects of progesterone receptor blockers on human granulosa-luteal cell culture secretion of progesterone, estradiol, and relaxin.
We have developed culture methods for human luteinizing granulosa cells (GLC) that support the timely and dynamic secretion of estrogen (estradiol-17beta; E(2)), progesterone (P(4)), and relaxin (Rlx) in patterns that mimic serum hormone concentrations during the luteal phase of the menstrual cycle. Additional hCG, to simulate rescue of the corpus luteum, prevented the normal decline in GLC hormone production. To test the importance of the P(4) receptor in P(4) production, GLC were treated in vitro with two P(4) receptor antagonists. Human GLC received one of two hCG support protocols: a Baseline group simulating the normal luteal phase or a Rescue group simulating early pregnancy. Baseline and Rescue groups were treated with either RU-486 or HRP2000 either early or late in the cell culture period. The effects of treatments or control on ovarian steroid and peptide hormone production were determined (significant difference was P < 0.05). In the Rescue group, late treatment resulted in an immediate and dramatic decline in E(2), P(4), and Rlx secretion to nearly nondetectable levels within 1 day after treatment, and hormones remained depressed for the remaining 10 days of culture. In contrast, early treatment resulted in a decline in steroid hormone secretion that returned to control levels within 5 days of cessation of treatment, and Rlx secretion was delayed for approximately 5 days more than in controls. The data support the hypothesis that P(4) may be a required autocrine factor, not only for its own production but also for the maintenance of full endocrine function of the corpus luteum.
VandeVoort
C A
CA
California Regional Primate Research Center, Division of Reproductive Biology, Department of Ob/Gyn and Institute of Toxicology and Environmental Health, University of California, Davis, California 95616, USA. cavandevoort@ucdavis.edu
Overstreet
J W
JW
Lasley
B L
BL
Stewart
D R
DR
D002478:Cells, Cultured; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D004958:Estradiol / Q000096:biosynthesis / Q000378:metabolism*; D005260:Female; D006107:Granulosa Cells / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D008184:Luteal Cells / Q000187:drug effects / Q000378:metabolism*; D015735:Mifepristone / Q000494:pharmacology; D009649:Norpregnadienes; D011247:Pregnancy; D011282:Pregnenediones / Q000494:pharmacology; D011374:Progesterone / Q000096:biosynthesis / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000037:antagonists & inhibitors*; D012065:Relaxin / Q000096:biosynthesis / Q000378:metabolism*; D013997:Time Factors
D006063:Chorionic Gonadotropin; D009649:Norpregnadienes; D011282:Pregnenediones; D011980:Receptors, Progesterone; D015735:Mifepristone; D011374:Progesterone; D004958:Estradiol; C094854:ulipristal; D012065:Relaxin